Ongoing ginseng clinical trials in June 2022
What is Ginseng?
Ginseng clinical trials have shown that it stimulates the central nervous system and helps the body to metabolize toxic substances produced by metabolism such as lactic acid and pyruvic acid (which are released in stressful situations). Studies shows that ginseng is an adaptogen and produces more energy efficiently.
Discovered 5000 years ago in the mountains in China, ginseng was the most revered of the herbs in ancient times. It remains one of the most widely used herbs in the world and its firming and healing properties make it one of the most important natural aids in toning human body. Ginseng and ginseng extract are used in various nutritional and food products, food supplements, flavored teas, energy drinks…the possibilities are endless.
Ongoing ginseng clinical studies in June 2022.
We reach out seven ongoing ginseng clinical researches on website USA FDA, they are now ongoing in China,USA,France, and Vietnam.
1. The clinical study to evaluate the efficacy and safety of compound glutamine capsule in prevention of chemotherapy induced mucositis in patients with gastric cancer and colorectal cancer
This Phase III clinical trial is a randomized, controlled, Double mind study sponsored by Meng Qiu, west China Hospital, located in Chengdu, China.
The drug/treatment of the study is a compound glutamine capsule and it’s simulated placebo. The capsule is comprised of Glutamine and Si-Jun-Zi-Tang, and the Si-Jun-Zi-Tang consists of Ginseng, Atractylodes macrocephala, Poria cocos and licorice, has been a treatment for many types of gastrointestinal diseases, such as gastrointestinal reactions induced by radiotherapy and chemotherapy, ulcerative colitis, irritable bowel syndrome.
The study is designed with two arms, started on June 30,2021 and is estimated to reach the primary completion on December31,2022.
2. A clinical trial to compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with the anti-angiogenic targeted drugs and ginsenoside Rg3 versus TACE alone in patient with Unresectable Hepatocellular Carcinoma
The responsible party of this multicenter, randomized controlled study is Eastern Hepatobiliary Surgery Hospital, located in Shanghai China. The two-year, interventional study started in December 2020 and is estimated to reach its primary completion in December 2022.
In this study, two groups with different treatments are set to compare the efficacy and safety, the combined group is treated with TKI Drugs + Ginsenoside Rg3 + TACE and the Single group treated with TACE alone.
3. A study to understand the effect of energy drink ingredients on cardiovascular function in USA.
The most common ingredients found in energy drinks are water, sugar, caffeine, taurine, and B vitamins, with varying inclusions of other ingredients, such as carnitine, glucuronolactone, inositol, guarana, ginkgo biloba leaf extract, thistle extract, and ginseng root extract.
Adverse event cases reports increased for customers who consumed energy drinks, reported symptoms include ventricular fibrillation, atrial fibrillation and cardia arrest.
This study aims to determine whether caffeine or combination of caffeine with taurine and Carnitine can change heart rate, blood pressure and the QTc interval of the EKG, based on the hypothesis that the the effects of the ingredients of energy drinks on the heart are mediated in part by interactions between caffeine, taurine and carnitine.
This dietary supplement study began on Jan1,2020 and is estimated to finish in March 2023.
4. A clinical study on the effects of ginseng in treatment for cancer-related fatigue in Texas, United States.
The purpose of this study is to learn whether panax ginseng can help to control fatigue and other symptoms including depression, anxiety and moon changes in patients with cancer and study the safety of ginseng.
The patients of this phase 2 research are advanced cancer/solid tumor patients. It is an interventional study with treatment of drug panax ginseng and dietary supplement as placebo, behaviors taken into consideration by questionnaires. It’s a long-term study as it actually started in Oct 2011 and is prepared to finish in Oct,2022. Let’s looking forward to the update.
5. A clinical study goals to test the effect of consuming of four natural extracts to modulate immune mechanisms is to close in this month.
In this ex vivo experimental study, healthy volunteers will consume the dietary supplement for 28 days and blood will be collected at the start and end of the study. The aim of this study was to evaluate ex vivo immune responses with and without stimulation after consumption of plant extracts and to identify the main mechanisms involved. The effect of consuming 4 plant extracts on the quality of life in healthy adults compared with placebo will also be analyzed.
The responsible party is Naturex SA(Part of Givaudan), and the ingredients of the dietary supplement are four botanical extracts included: Acerola, panax ginseng, echinacea and quillaja. The treatment of this interventional study is this for botanical extracts supplement. The primary completion is estimated to reach in coming month.
6. A clinical trial aims to assess the efficacy of Shen Cao Gan jiang Tang on mild and moderate Covid-19 patients.
The treatment formula of this study is Shen Cao Gan Jiang Tang. It is based on an ancient formula Gan Cao Gan Jiang Tang(GGT) and combination with Ginseng as GGT strengthening and rebalancing Qi(immune system).
The objectives of this study
🎯To evaluate the effectiveness of Shen Cao Gan Jiang Tang beyond standard of care in reducing duration and severity of symptoms compared with standard of care in COVID19 patients mild and moderate.
🎯To analyze the effect of Shen Cao Gan Jiang Tang beyond standard of care in terms of reducing the proportion of patients progressing to severe compared with standard of care in mild and moderate COVID19 patients.
🎯To assess the effectiveness of Shen Cao Gan Jiang Tang beyond standard of care in terms of reducing the time needed to respond discharge standards versus standards of care in mild and moderate COVID19 patients.
The study actually started on Aug 20,2021 in Vietnam and was estimated to reach completion on Aug 20,2022, Interested in the publications?
7. A clinical study in purpose of evaluation of cutaneous tolerance of ten products by primary irritant patch test is coming to close in this month.
24 hours single application patch test on the back. The treatment of this single-arm study is ten products (S01~S10) and two blank (BK1, BK2):
S01 “Functional Peptides Recovering Essence EX”
S02 “Advanced Revitalizing Eye Cream”
S03 “Advanced Revitalizing Lotion”
S04 “NB-1 Anti-Sensitive Repair Activator”
S05 “NB-1 Anti-Sensitive Repair Toning Extract”
S06 “Ginseng Vitality Serum”
S07 “Ginseng Revitalizing Age-defense Essence Cream”
S08 “Ginseng Age-defense Eye Cream”
S09 “Revital Energy Balance Gel”
S10 “Revital Energy Tightening Body Lotion”
The study started on Dec 17, 2021, condition was Dermatitic Reaction of the Face, we may hunt for news related to the study.
We’d love to hear from you, and we will
Reply Within 12 Hours.
10+ years industry experience makes the fast shipping come true. Leadtime less than 7days and OEM/OEM samples can be ready for ship within 7 days, for instance.
And free sample available for you.